Investors
Partners
Recludix and Sanofi have established a strategic partnership to develop and commercialize first-in-class oral small molecule STAT6 (signal transducer and activator of transcription 6) inhibitors for patients with immunological and inflammatory diseases. STAT6 is believed to play a key role in multiple dermatological and respiratory diseases.
Recludix will advance the STAT6 inhibitor from preclinical development through the start of Phase 2 clinical trials. Sanofi is responsible for worldwide clinical development and commercialization thereafter. Recludix has an option to participate in an equal profit-sharing arrangement in the U.S., which includes certain co-promotion activities.
To learn more about the partnership, read the press release.
Recludix has a collaboration with Eli Lilly to access Lilly TuneLab, a pioneering artificial intelligence and machine learning (AI/ML) platform designed to accelerate the development of new medicines by providing biotech companies access to powerful drug discovery models that have been trained on Lilly’s proprietary research data.
This collaboration will amplify the advanced computational capabilities of Recludix’s platform, thereby accelerating the progression of its novel SH2 domain discovery pipeline.
To learn more about the collaboration with Lilly, read the press release.